18
NEWS
FSL3 in new loop
Ypsomed and CamDiab have
launched the first system
for automated insulin
dosing (AID) with Abbott's
FreeStyle Libre 3 (FSL3).
Mylife Loop is now authorized to
work with Abbott's FreeStyle Libre
3 sensor in Germany. The mylife
YpsoPump and the FSL3, combined
with the mylife CamAPS FX algorithm
from CamDiab, form an intelligent
and automated insulin delivery
system (AID) designed to help people
with Type 1 diabetes in order to
better control their glucose levels
and alleviate the burden of daily
diabetes management.
The mylife Loop solution is
designed to create an intelligent,
automated process for insulin dosing
based on real-time glucose data. A
person's glucose level is monitored
continuously and the appropriate
amount of insulin is administered
at the right point in time, making
selfcare simpler and easier.
People with Type 1 diabetes spend
a lot of time on their daily diabetes
management, time and effort that
has been shown to be significantly
reduced by using the CamAPS,
part of mylife Loop1. Ypsomed
already launched mylife Loop in
partnership with CamDiab in early
summer 2022 in several countries.
Users report more freedom in their
daily lives: they have more time
for their families, are more active
and can sleep better at night. The
mylife Loop solution also gives the
parents of children with diabetes
a good overview of their child's
glucose values at any time, as well
as control via a smartphone app
so they can respond accordingly
where necessary.
Choice
By enabling the FSL3 sensor to
work with mylife Loop, people with
diabetes now have the option of
choosing between two sensors, the
Dexcom G6 and the FSL3, and of
customising their loop.
Sébastien Delarive, Chief Business
Officer Diabetes Care at Ypsomed,
comments, "We are convinced
that the major challenges facing
society can only be solved through
partnerships. We are therefore
proud to expand our offering with
Abbott to give the users of our mylife
YpsoPump more freedom of choice
in managing their diabetes. Our
compact and easy-to-use insulin
pump authorized to work with
Abbott's latest sensor and CamDiab's
adaptive hybrid closed-loop app
will change the lives of thousands of
people affected by diabetes."
The integrated AID solution
authorized to work with the
FreeStyle Libre 3 sensor is currently
available in Germany, with other
European countries to follow in 2023.
The mylife Loop offering is currently
available for Android; iOS will follow
in the second half of 2023.
www.ypsomed.co.uk
Link to insulin pens
In further news from Abbott, Novo
Nordisk has announced that UK users
of the Abbott FreeStyle LibreLink app
can now connect to its smart insulin
pens. People can connect the app to
their Novo Nordisk smart, connected
pens (including the Novo Nordisk
NovoPen 6 and the NovoPen Echo
Plus). Users of the Abbott FreeStyle
LibreLink app with FreeStyle Libre
glucose sensing technology can
see a range of information related
to their diabetes, including dose
timing, the amount of insulin taken,
and how those metrics impact their
individual glucose patterns. When
users tap their pen against their
smartphone, they automatically
upload their insulin dose data to the
FreeStyle LibreLink app. It all appears
viewable alongside their glucose
data, all in one place, saving time and
eliminating missing, incomplete or
inaccurate data.
"Individually, these two
technologies provide valuable
information for people managing
their diabetes," said Somerset
Foundation Trust nurse consultant
Su Down. "Linked together, however,
they can provide additional insight
into the impact of both dosing and
timing of injection on glucose levels.
Providing people with diabetes and
HCPs with this insightful information
offers an additional perspective,
much like adding another piece to
the puzzle - we see more of the
overall picture on which to base
diabetes management decisions."
1 Chen et al Diabetes Care,
2021;44(7):e148-e150.
www.freestylelibre.co.uk